CEACAM5 and colorectal carcinoma: Similarly, MUC16, in combination with other glycoproteins, such as CEA, CA19.9, CYFRA21-1, and CA72-4, has been studied as a biomarker for the diagnosis and treatment guidance of CRC patients [119].